How chemically and functionally similar are methamphetamine and amphetamine salts?

Chemical and Functional Similarity Between Methamphetamine and Amphetamine Salts

Methamphetamine and amphetamine salts are structurally nearly identical—differing only by a single methyl group—and share overlapping mechanisms of action, though methamphetamine demonstrates greater potency at the dopamine transporter level and produces more pronounced physiological effects at equivalent doses. 1

Chemical Structure

• Methamphetamine differs from amphetamine by only one methyl group attached to the nitrogen atom, making them structural analogues within the same sympathomimetic amine class. 2
• Amphetamine salts (such as mixed amphetamine salts used therapeutically) contain a 3:1 ratio of d-amphetamine to l-amphetamine isomers. 3
• Both compounds are classified as non-catecholamine sympathomimetic amines with CNS stimulant properties. 3

Mechanism of Action Similarities

Both drugs share core pharmacological mechanisms: 1

• Inhibition of dopamine and norepinephrine transporters, preventing reuptake into presynaptic neurons
• Inhibition of vesicular monoamine transporter 2 (VMAT2), disrupting neurotransmitter storage
• Inhibition of monoamine oxidase activity, reducing neurotransmitter breakdown
• Enhancement of dopamine and norepinephrine release into the extraneuronal space
• Optimization of prefrontal cortex activity, improving executive function and attention in ADHD patients

Key Functional Differences

Despite structural similarity, important functional distinctions exist:

Potency at the Dopamine Transporter

• Methamphetamine produces 5-fold greater dopamine release than amphetamine at the same voltage and concentration in vitro, and releases twice as much intracellular calcium. 4
• Methamphetamine inhibits dopamine transporter-mediated clearance more efficiently than amphetamine in vivo, resulting in greater extracellular dopamine accumulation. 4
• These differences persist even at physiological membrane potentials. 4

Regional Neurotransmitter Effects

• In the nucleus accumbens: Amphetamine raises glutamate levels while methamphetamine does not. 5
• In the prefrontal cortex: Methamphetamine raises glutamate levels while amphetamine does not; amphetamine produces greater dopamine elevation than methamphetamine. 5
• Both drugs raise dopamine levels similarly in the nucleus accumbens. 5

Abuse Potential and Subjective Effects

• Human self-administration studies show equivalent abuse potential between intranasal methamphetamine and d-amphetamine, with 41% drug choices under low monetary alternative conditions. 6
• Methamphetamine produces more prominent cardiovascular effects (particularly heart rate elevation) and higher subjective ratings of "high" compared to amphetamine at equivalent doses. 6
• At low behaviorally-activating doses, the drugs are largely equipotent, though methamphetamine shows greater potency when discrete salient stimuli are present. 7

Neurotoxicity Profile

• Methamphetamine and amphetamine are equipotent at producing lethal hyperthermia and neurotoxicity when administered at equimolar doses (4×2.0 mg/kg amphetamine vs 4×2.2 mg/kg methamphetamine) during the waking cycle. 8
• Both produce 70% striatal dopamine depletions and neurodegeneration in cortex and thalamus at toxic doses. 8
• Methylphenidate requires approximately 10-fold higher doses on a mg/kg basis to produce similar hyperthermic effects. 8

Clinical Implications

Therapeutic Use

• Both methylphenidate and amphetamine classes are first-line pharmacotherapies for ADHD, with more than 90% of patients responding to one of the psychostimulants when both classes are tried. 9, 1
• Both share similar adverse effect profiles including decreased appetite, sleep disturbances, increased blood pressure and pulse, headaches, irritability, and stomach pain. 1
• Effects on growth (height and weight) are dose-related and similar for both methylphenidate and amphetamine. 1

Pharmacokinetics

• Amphetamine salts show dose-proportional pharmacokinetics with peak plasma concentrations at approximately 3 hours post-dose. 3
• The d-amphetamine isomer has a shorter elimination half-life (9.77-11 hours) compared to l-amphetamine (11.5-13.8 hours). 3
• Both drugs undergo similar metabolic pathways including oxidation to form 4-hydroxyamphetamine and alpha-hydroxy-amphetamine, with CYP2D6 involvement. 3
• Urinary excretion is highly pH-dependent for both compounds, with alkaline urine reducing renal elimination. 3

Important Clinical Caveats

• The single methyl group difference translates to meaningful pharmacodynamic distinctions despite structural similarity, particularly regarding dopamine transporter effects and regional neurotransmitter patterns. 4, 5
• Methamphetamine's greater potency at the dopamine transporter may contribute to its enhanced euphoric and addictive properties compared to amphetamine in abuse contexts. 4
• When used illicitly, average daily methamphetamine consumption (>1,500 mg oral amphetamine equivalent) far exceeds maximum therapeutic amphetamine doses (60mg), which may explain limited efficacy of prescription stimulant treatment for methamphetamine use disorder. 10